UNSPSC 51332876: Thioproperazine mesylate

This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71P630M192, chemically known as phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)-, dimethanesulfonate but more generally known as thioproperazine mesilate, which bears US NIH Compound Identifier 92178. Most nations, for tariff and trade purposes, schedule thioproperazine mesylate under HS 29350090.

As of Q4 2014, THIOPROPERAZINE MESYLATE remains US FDA's Preferred Term for this commodity. Thioproperazine mesylate bears US NLM identifiers UMLS ID C0770896 and NCI Concept Code C80010. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51332876 Thioproperazine mesylate is a Commodity code for a pharmaceutical antipsychotic agent, though recent state and local procurement activity under this code does not reflect the nominal pharmaceutical scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB for Naloxone and Drug Deactivation Systems—appears to be a tagging misalignment, as naloxone is an opioid antagonist used for overdose reversal and drug deactivation systems are harm-reduction equipment, neither of which aligns with thioproperazine mesylate's clinical application as an antipsychotic. The code shows minimal recent activity and does not support a reliable characterization of what state and local governments actually procure under this UNSPSC classification.

Seminole County's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required vendors to submit bids electronically, include all shipping and delivery costs in proposals, and comply with drug-free workplace certification and E-Verify requirements. The contract was structured as a fixed-fee agreement with an initial two-year term plus an optional one-year renewal and a three-month probationary period permitting termination at will. The opportunity indicated potential FEMA funding and compliance with federal environmental regulations. No set-aside designations were specified. The sparse recent-opportunity record and the apparent mismatch between the code's pharmaceutical scope and the actual naloxone procurement suggest this code warrants close verification before pursuit.